The Global Coalition on Aging is excited to again be leading the special track on ICTs and Older Persons at the 2023 WSIS Forum in partnership with ITU. Join us for this series of thought-provoking panels exploring how digital technology is transforming the future of aging and to learn more about how individuals and organizations…

In this video, GCOA member Surya Kolluri, head of the TIAA Institute, sits down with Dean Erika James of Wharton for a Fireside Chat at the 2023 Pension Research Council Symposium "Diversity, Inclusion, and Inequality: Implications for Retirement Income Security and Policy."

Antimicrobial resistance is one of the defining global problems of our time. Drug-resistant bacterial infections killed an estimated 1.27 million people in 2019. By 2050, 10 million lives annually could be lost to antimicrobial resistance, and annual global gross domestic product could fall by between 1.1 per cent and 3.8 per cent. Fortunately, Chinese policymakers, physicians and patients have shown what is possible when they focus collective efforts on antimicrobial resistance.

As policymakers search for potential cuts to the national budget, they risk jeopardizing the country’s most cost-effective use of healthcare dollars: biomedical innovation regarding vaccines , prescription drugs, and emerging therapies, including antibodies. As the nation rapidly ages, protecting this pipeline of medicine will not only improve health outcomes but will do so at a lower cost by reducing more expensive hospital and primary care.

The Global Coalition on Aging (GCOA) and the Global Heart Hub have released a global position paper “Heart Valve Disease: Harnessing Innovation to Save Lives, Mitigate Costs, and Advance the Healthy Aging Agenda.” The report builds upon on a December 2022 GCOA-GHH roundtable of cross-sector experts and examines how behavior and policy change can best address heart valve disease in our 21st century.